Government response to the ACMD’s review of the evidence on the use and harms of Cumyl-PeGaClone.



Documents

Government response to the ACMD’s advice on Cumyl-PeGaClone and other synthetic cannabinoid receptor agonists

HTML

Details

Government response to the Advisory Council on the Misuse of Drugs’ review of the evidence on the use and harms of Cumyl-PeGaClone.

Published 25 July 2023